Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 4
2009 4
2010 2
2011 3
2012 3
2013 1
2014 6
2015 8
2016 4
2017 5
2018 8
2019 6
2020 8
2021 12
2022 9
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
Schaeffers AWMA, Devriese LA, van Gils CH, Dankbaar JW, Voortman J, de Boer JP, Slingerland M, Hendriks MP, Smid EJ, Frederix GWJ, de Bree R. Schaeffers AWMA, et al. Among authors: de boer jp. PLoS One. 2023 Nov 27;18(11):e0294147. doi: 10.1371/journal.pone.0294147. eCollection 2023. PLoS One. 2023. PMID: 38011186 Free PMC article.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trněný M, Provencio M, Jäger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert A, Armand P. Ansell SM, et al. Among authors: de boer jp. Blood Adv. 2023 Oct 24;7(20):6266-6274. doi: 10.1182/bloodadvances.2023010334. Blood Adv. 2023. PMID: 37530622 Free PMC article. Clinical Trial.
Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study.
Mols F, Schoormans D, Netea-Maier R, Husson O, Beijer S, Van Deun K, Zandee W, Kars M, Wouters van Poppel PCM, Simsek S, van Battum P, Kisters JMH, de Boer JP, Massolt E, van Leeuwaarde R, Oranje W, Roerink S, Vermeulen M, van de Poll-Franse L. Mols F, et al. Among authors: de boer jp. Thyroid Res. 2023 Jul 10;16(1):23. doi: 10.1186/s13044-023-00165-5. Thyroid Res. 2023. PMID: 37424010 Free PMC article.
Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.
Ykema BLM, Gini A, Rigter LS, Spaander MCW, Moons LMG, Bisseling TM, de Boer JP, Verbeek WHM, Lugtenburg PJ, Janus CPM, Petersen EJ, Roesink JM, van der Maazen RWM; DICHOS study group; Aleman BMP, Meijer GA, van Leeuwen FE, Snaebjornsson P, Carvalho B, van Leerdam ME, Lansdorp-Vogelaar I. Ykema BLM, et al. Among authors: de boer jp. Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2157-2168. doi: 10.1158/1055-9965.EPI-22-0019. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 36166472 Free PMC article.
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH, van der Heijden M, Wesseling FWR, de Ruiter EJ, Heymans MW, Terhaard C, Vergeer MR, Buter J, Devriese LA, de Boer JP, Navran A, Hoeben A, Vens C, van den Brekel M, Brakenhoff RH, Leemans CR, Hoebers F. de Roest RH, et al. Among authors: de boer jp. Radiother Oncol. 2022 Oct;175:112-121. doi: 10.1016/j.radonc.2022.08.013. Epub 2022 Aug 13. Radiother Oncol. 2022. PMID: 35973619 Free article.
Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center.
Piek MW, de Vries LH, Donswijk ML, de Keizer B, de Boer JP, Lodewijk L, van Leeuwaarde RS, Vriens MR, Hartemink KJ, van der Ploeg IMC. Piek MW, et al. Among authors: de boer jp. Eur J Nucl Med Mol Imaging. 2022 Jun;49(7):2392-2400. doi: 10.1007/s00259-022-05679-y. Epub 2022 Jan 15. Eur J Nucl Med Mol Imaging. 2022. PMID: 35031811
[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.
Vos JL, Zuur CL, Smit LA, de Boer JP, Al-Mamgani A, van den Brekel MWM, Haanen JBAG, Vogel WV. Vos JL, et al. Among authors: de boer jp. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2010-2022. doi: 10.1007/s00259-021-05610-x. Epub 2021 Dec 27. Eur J Nucl Med Mol Imaging. 2022. PMID: 34957526 Free PMC article. Clinical Trial.
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL. Vos JL, et al. Among authors: de boer jp. Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9. Nat Commun. 2021. PMID: 34937871 Free PMC article. Clinical Trial.
71 results